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ABSTRACT: Recently, there has been an increasing interest for
utilizing the host immune system to fight against cancer. Moreover,
cancer vaccines, which can stimulate the host immune system to
respond to cancer in the long term, are being investigated as a
promising approach to induce tumor-specific immunity. In this
work, we prepared an effective cancer vaccine (denoted as
“vacosome”) by reconstructing the cancer cell membrane,
monophosphoryl lipid A as a toll-like receptor 4 agonist, and egg
phosphatidylcholine. The vacosome triggered and enhanced bone
marrow dendritic cell maturation as well as stimulated the
antitumor response against breast cancer 4T1 cells in vitro.
Furthermore, an immune memory was established in BALB/c mice after three-time preimmunization with the vacosome. After that,
the immunized mice showed inhibited tumor growth and prolonged survival period (longer than 50 days). Overall, our results
demonstrate that the vacosome can be a potential candidate for clinical translation as a cancer vaccine.
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1. INTRODUCTION
Vaccines have been considered as one of the most effective
approaches in controlling infectious diseases. At the same time,
the scientific community also proposes to develop cancer
vaccines to prevent cancer, which is expected to be similar to
the conventional vaccine in the prevention of infectious
diseases.1−4 The basic mechanism behind cancer vaccination
relies on the activation of antigen-presenting cells (APCs),
such as dendritic cells (DCs) and macrophages, together with
processing of the cancer-related antigens provided by the
vaccines.5,6 Then, these activated APCs will direct the
differentiation of T cells by presenting the processed antigens.
Among the various subpopulations derived from T cells, the
major responsibility of CD8+ cytotoxic T lymphocytes (CTLs)
is to attack tumor cells, while memory T cells are generated for
the long-term protection.7,8 Because of the fundamental
position of the activated APCs, it is important to consider
promoting the activation of APCs and delivering the cancer-
related antigens to APCs, when preventive cancer vaccines are
designed.
Monophosphoryl lipid A (MPLA), a toll-like receptor 4
(TLR4) agonist, is derived from the cell wall of nonpathogenic
Salmonella.9,10 MPLA has been employed in human trials in
vaccine for malaria, HIV-1, and meningococcal type B disease
because it can bind and activate membrane-associated TLR4
during uptake by APCs, thereby enhancing cell-mediated
immunity to a variety of antigens.11,12 However, there are still
some challenges in the development of MPLA as a preventive
cancer vaccine, such as its hydrophobicity. As for other issues,
the administration of only MPLA is not enough to promote the
priming of a cancer-specific adaptive immune response because
the APCs lack the antigen. Although the administration of
MPLA would result into a generic activation of the immune
system, which has been systematically investigated by
researchers, there is still low potential against the tumor
without the specificity given by the antigen. At present,
different strategies have been proposed to utilize the immune
activation of MPLA, for example, combination with various
drug-delivery systems.10,13,14 Therefore, some formulation
improvements are needed to develop MPLA-related preventive
cancer vaccines.
Several tumor-specific antigens, such as tumor-specific
peptides,15,16 proteins,17 mRNA,18 or DNA,19 have been
utilized to develop cancer vaccines to trigger a specific
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antitumor immune response. Although they are specific
enough, the synthesis and isolation processes for such antigens
can be time-consuming and expensive. Cancer cell membranes
contain plenty of tumor-specific antigens. Moreover, these
antigens can be obtained directly from the isolated cell
membranes retaining their bioactivity.20−22 In addition, the
easy cell membrane isolation process makes this approach time
effective and inexpensive.4 However, the cancer cell membrane
cannot work as a preventive cancer vaccine by itself because of
the limited ability in boosting immune response.23
Recently, nanomaterials have been proved to codeliver
antigens and adjuvants in the same carriers and induce robust
immune responses.24−28 Liposomes, a Food and Drug
Administration (FDA)-approved nanomaterial, present a
phospholipid bilayer structure, which is similar to the structure
of the cell membrane.10 In terms of composition, liposomes,
MPLA, and cell membrane mainly consist of phospholipid,
which makes liposomes as an ideal nanomaterial to develop the
potential ability of MPLA and cancer cell membranes as
preventive cancer vaccines. In this work, we prepared a
biohybrid liposome (denoted here as “vacosome,” short for
“vaccine liposomes”) by reconstituting MPLA, 4T1 cancer cell
membranes, and common lipid [1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[amino(polyethyleneglycol)-2000],
DSPE-PEG-2000, egg phosphatidylcholine, EPC, and choles-
terol] (Scheme 1). We first investigated the efficacy of the
vacosome in vitro by inducing BALB/c mice bone marrow
dendritic cell (BMDC) maturation and by stimulating
splenocytes to eliminate 4T1 cells. In vivo experiments were
conducted in vacosome-immunized BALB/c mice, and the
production of cytokines, such as interleukin-12 (IL-12p70),
tumor necrosis factor-α (TNF-α), and interferon-γ (IFN-γ),
was analyzed to evaluate the activity of the immune system.29
To evaluate whether the vacosome could function as a
preventive cancer vaccine in vivo, a 4T1 breast cancer tumor
model was selected for this study. The established in vivo
immune memory after vacosome treatment was evaluated by
the differentiation of the central memory T cells (TCM) and
effector memory T cells (TEM).
30 Additionally, the efficacy of
the vacosome in protecting immunized mice against tumor
Scheme 1. Fabrication Process of the Vacosome and the Immune Response Induced by the Vacosome In Vivo
Figure 1. Preparation and characterization of the vacosome. The percentage of mature CD11c+-gated BMDCs induced with different amounts of
(A) MPLA, (B) CM, and (C) lipid matrix. (D) Z-average diameter and (E) zeta potential of MPLA@Lip, CM, and vacosome. (F) TEM image of
the vacosome. NC: BMDCs cultured in medium without any materials. PC: BMDCs cultured in medium with lipopolysaccharides (LPS). Data
represent the mean ± SD of triplicate experiments (n = 5; *P < 0.05, ***P < 0.001).
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challenge and in prolonging the overall survival was confirmed
by analyzing the ratio of CTLs to CD 3+ cells and the ratio of
regulatory T cells (Treg) to CD 4
+ cells in the tumor area.
2. RESULTS AND DISCUSSION
The vacosome prepared in this study consisted of three major
elements: an adjuvant (MPLA), an antigen (4T1 cell
membrane, CM), and a lipid matrix (EPC, DSPE-PEG-2000,
and cholesterol). The ability of these three individual
components in inducing BMDC maturation was investigated
by flow cytometry to choose the ideal amount of each
component for the synthesis of the vacosome (Figure 1A−C).
As shown in Figure 1A, when increasing the amount of
MPLA (from 0.1 to 1 μg), the percentage of matured BMDCs
also increased. However, the maturation of BMDCs reached a
plateau when the amount of MPLA exceeded 1 μg. As for the
amount of CM (Figure 1B), the highest amount of CM (1600
μg) led to the maximum expression level of CD86 compared to
the other groups tested. Additionally, the low immunogenicity
of the lipid matrix was shown by coculturing BMDCs with
various amounts of lipid matrix from 100 to 1000 μg (Figure
1C). According to the results, 1 μg of MPLA and 1.6 mg of
CM were chosen to further fabricate the vacosome. As
measured by dynamic light scattering (DLS), the diameters of
MPLA@Lip, CM, and vacosome were 105.7 ± 2.3, 246.1 ±
1.2, and 122.4 ± 3.6 nm, respectively (Figures 1D and S1a).
Compared with the size of MPLA@Lip, the increasing size in
the vacosome could be attributed to the presence of the cell
membrane.
Additionally, the long-term stability of the vacosome in 1×
phosphate-buffered saline (pH 7.4) was also evaluated by DLS.
Although the diameter of the vacosome increased from 109.3
± 2.1 to 147.9 ± 3.3 nm, the size of the vacosome was still less
than 200 nm (the critical diameter of nanoparticles for the
enhanced permeability and retention effect) (Figure S1b). The
zeta potential was also investigated (Figure 1E), and a decrease
in the zeta potential was observed in the vacosome (from 7.3 ±
0.3 mV for MPLA@Lip to 4.3 ± 0.4 mV for the vacosome),
which was due to the negative zeta potential of the CM (−6.25
± 0.6 mV).
The morphologies of the vacosome, MPLA@Lip, and CM
were also evaluated by transmission electron microscopy
(TEM, Figures 1F and S1c,d). As shown in the TEM results,
the diameter of the vacosome in the TEM experiments is
slightly different from that in the DLS results, attributed to the
nature of TEM imaging on dry samples as compared to the
measuring size by DLS in the solution form.31 All of the above-
mentioned results show that the vacosome system was
successfully prepared utilizing a fixed combination of MPLA,
mixture lipid, and cancer cell membrane.
After the synthesis of the vacosome, its biocompatibility and
cellular uptake were further investigated in vitro. First, we
evaluated the biocompatibility of the system by coculturing the
vacosome with BMDCs for 1 day to 3 days (Figure 2A).
With the exception of the positive control (PC) groups, the
other groups showed similar cell viability, which indicates that
the vacosome is nontoxic in vitro over BMDCs. Then, we
further evaluated whether the vacosome could have enhanced
uptake in BMDCs compared with MPLA@Lip. As shown by
the flow cytometry results (Figures 2B and S1e, similar
percentages of fluorescein isothiocyanate (FITC+) BMDCs
(which means the BMDCs taking-up FITC-labelled Lip&F,
MPLA@Lip&F, or vacosome&F) were observed among the
tested groups for 3 and 6 h, while more FITC+ BMDCs were
found in the vacosome-treated group after 24 and 48 h.
In addition to biocompatibility and cellular uptake, the
functionality, such as effective immune activation, is also a
necessary part of vaccines. The composition of the vacosome,
such as MPLA and 4T1 cell membrane, was proved in
inducing BMDC maturation (Figure 1). To explore whether
the vacosome could induce similar or enhanced immune
activation, BMDCs were cocultured with various formulations
from 1 day to 3 days (Figure 2C−E). After the first 24 h, PC
(56.4 ± 4.5% in CD86+, 44.7 ± 4.7% in CD80+) showed
Figure 2. In vitro investigation of the vacosome. (A) Cell viability of BMDCs treated with different formulations. NC: BMDCs cultured only with
medium; PC: with 1% Triton X-100; lipid control (LC): with DSPE-PEG2000, EPC, and cholesterol; (B) Uptake of DSPE-PEG-2000-FITC
labelled Lip&F, MPLA@Lip&F, and vacosome&F by BMDCs in vitro. DC maturation gated in CD11c+ by vacosome for (C) 24 h, (D) 48 h, and
(E) 72 h coculture; NC: BMDCs cultured only with medium; PC: with 1 μg MPLA; LC: with DSPE-PEG2000, EPC, and cholesterol. (F) Cell
viability of 4T1 cells after 24 h’ incubation. NC: 4T1 cells cultured with BMDCs and splenocytes; MPLA: with MPLA-induced BMDCs and
splenocytes; LPS: with LPS-induced BMDCs and splenocytes, LC: with DSPE-PEG2000, EPC, and cholesterol-induced BMDCs and splenocytes;
MPLA + CM: with MPLA and CM-induced BMDCs and splenocytes; CM: with CM-induced BMDCS and splenocytes; vacosome: with
vacosome-induced BMDCs and splenocytes. Data represent the mean ± SD of triplicate experiments (n = 5; *P < 0.05, ***P < 0.001).
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effective and quick immune activation, whereas CM, MPLA@
Lip, and vacosome exhibited relatively low immune stimulation
on BMDCs. After 48 h, CM (44.2 ± 2.0% in CD86+, 35.4 ±
1.8% in CD80+), MPLA@Lip (51.7 ± 1.2% in CD86+, 38.9 ±
0.5% in CD80+), and vacosome (64.2 ± 2.9% in CD86+, 53.2
± 4.0% in CD80+) groups exhibited a significant increase in
the maturation percentage compared with the PC groups (57.8
± 4.5% in CD86+, 42.7 ± 4.7% in CD80+). After 3 days
incubation, the vacosome groups (82.4 ± 1.4% in CD86+, 80.8
± 1.7% in CD80+) showed the highest maturation percentage.
These results suggested that the vacosome can significantly
promote immune activation compared to MPLA@Lip and CM
as a result of the enhanced immune effect caused by
incorporating the tumor cell antigen and immunostimulatory
adjuvant simultaneously into the same carrier.24
Since the aim of using vacosome is to protect the immunized
mice from tumor challenge, the vacosome is supposed to
activate and educate the immune system to be prepared in
fighting against cancer cells. To investigate whether the
vacosome could promote the immune system to kill cancer
cells in vitro, BMDCs were first incubated with different
formulations for 3 days in order to mature BMDCs and
process antigens. Then, these BMDCs were further cocultured
with splenocytes (since spleen is one of the most important
immune organs in the body) for another 3 days. Finally, the
vaccination efficacy of the vacosome was demonstrated by
evaluating the cell viability of 4T1 cells after 1 day of coculture
with activated splenocytes and BMDCs (Figures 2F and S1f).
The cell viability of 4T1 cells in the negative control (NC)
group was regarded as a standard control (marked as 100%).
The immune cells (BMDCs, splenocytes, and other
splenocyte-derived cells) showed enhanced antitumor ability
after treatment with the vacosome compared with immune
cells treated with MPLA + CM (as for the control with MPLA
+ CM, it was used to evaluate the effect of formulating
adjuvant and antigen within the same formulation compared to
a simple mix of the two components). According to this result,
we hypothesized that the vacosome can more effectively
promote DC maturation and deliver antigen to DCs. In order
to verify our hypothesis and explore the immunological
mechanisms of action, we next investigated the vacosome in
vivo.
With a focus on the potential clinical translation of the
vaccine, the short-term safety profile of the vacosome was also
evaluated in vivo. During the treatment duration, the body
weight of each mouse was recorded, as shown in Figure S1g−j.
The mice injected with different formulations (saline, CM,
MPLA@Lip, and vacosome) showed a similar increasing trend
in bodyweight. Additionally, kidney, liver, and heart were
collected from the mice in each group, and then hematoxylin
and eosin (H&E) staining was utilized to evaluate the tissue
morphology (Figure 3E−P). According to the H&E staining
Figure 3. Biocompatibility of the vacosome in vivo. H&E staining results of kidney treated with (A) saline, (B) CM, (C) MPLA@Lip, and (D)
vacosome. Liver treated with (E) saline, (F) CM, (G) MPLA@Lip, and (H) vacosome. Heart treated with (I) saline, (J) CM, (K) MPLA@Lip,
and (L) vacosome.
Figure 4. Immune activation of the vacosome in vivo. (A) Treatment plan for immunized BALB/c mice. The concentration of (B) IL-12p70, (C)
TNF-α, and (D) IFN-γ in the serum 7, 14, and 28 days after stimulation. Data represent the mean ± SD (n = 5; *P < 0.05, **P < 0.01, ***P <
0.001).
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results, there was no obvious inflammatory cell infiltration in
the tissues, and the tissue organization was physically normal
without any swelling, adhesion, or hyperplasia, which indicates
that the vacosome did not show cardiotoxicity, nephrotoxicity,
or liver toxicity in the normal tissue even after 28 days of
treatment. Overall, these results indicated that the vacosome
was safe in vivo; hence, we further explored the immunological
profile of the vacosome in vivo.
To evaluate the immune activation state in healthy BALB/c
mice after different stages of the preimmunization scheme with
the formulation (Figure 4A−D), serum was collected and
analyzed by cytometric bead array for the detection of the
secreted IL-12p70, TNF-α, and IFN-γ (Figure S2). IL-12p70 is
produced by activated DCs and is important for IFN-γ
production by lymphocytes. TNF-α is also highly related to
cancer immunity by causing apoptosis and inflammation.
Activated CD8+ T cells can generate IFN-γ which can induce
apoptosis in the target cells. Thus, these three cytokines were
selected to evaluate the immune activation state.32−34 Addi-
tionally, as a Th2 related cytokine, IL-6 was also investigated
(Figure S3a). At 7 days after the first immunization, there was
not a significant difference in the secretion levels of IL-12p70,
TNF-α, and IFN-γ in mice treated with different formulations.
Three days post the second vaccination (14 days), an increase
in the secretion levels of these three cytokines was detected in
mice treated with the vacosome. At 28 days (3 days after the
third vaccination), the mice treated with the vacosome still
showed the highest levels of IL-12p70 (33.5 ± 6.5 pg/mL),
TNF-α (49.9 ± 7.8 pg/mL), and IFN-γ (55.9 ± 10.3 pg/mL).
Overall, for mice treated with the vacosome, from 7 to 14 days,
the cytokine secretion level increased more than 3-fold.
However, from 14 to 28 days, the increasing trend slowed
down (Figure 4B−D). We hypothesize this could be due to the
fact that the process of creating an adaptive immune response
after vaccination have two different waves of immune
activation. After the first immunization, the immune system
takes up to 72 h to mount an adaptive immune response of
small magnitude with lower levels of cytokines.35 Upon the
second exposure to the antigen and adjuvant, the magnitude of
the immune response reaches the peak, which will remain
constant also after further rechallenge; thus, even after the
stimulation, the cytokine secretion level cannot be further
significantly improved.36,37 All these results revealed that the
vacosome effectively stimulated the immune system and made
the immune system secrete related cytokines which can fight
against with cancer cells.
Next, we investigated whether the immunized mice can
effectively reject 4T1 cells in a tumor challenge experiment. As
described in Figure 5A, after three vaccinations with different
formulations (saline, MPLA@Lip, CM, and vacosome), the
mice were challenged by 4T1 cells at day 3 post the final
vaccination (marked as day 0 in the tumor stage). The tumor
growth was monitored starting from day 2 post tumor cell
challenge. The CM vaccination group tumor could partially
inhibit tumor progression as compared to saline groups
(Figure 5B,C), and a similar phenomenon was also proved
by Cheung et al.23 This is due to the fact that the
administration of antigens only is not able to prime a
proinflammatory immune response while often resulting into
a tolerogenic effect.38 MPLA@Lip groups showed increased
tumor growth inhibition efficacy compared with the CM
formulation (Figure 5D). In these three groups, the tumor size
exhibited obvious individual differences, although the tumor
size in mice treated with MPLA (747.4 ± 454.7 mm3) was
more average than those in saline (1725.3 ± 1158.2 mm3) and
CM (1488.0 ± 1107.4 mm3) groups. Most importantly, the
mice treated with the vacosome showed more than 10-times
limited tumor size (76.0 ± 63.9 mm3) compared to all other
formulations (Figures 5E,F, S4). Additionally, the long-term
survival rate was investigated in the immunized mice (Figure
Figure 5. Efficacy of vacosome preimmunization in 4T1-bearing BALB/c mice. (A) Schematic illustration of the experimental design for vacosome
administration to inhibit tumor growth. Tumor growth of mice treated with (B) saline, (C) CM, (D) MPLA@Lip, and (E) vacosome. Each line
indicates the tumor size of the individual mouse. (F) Average tumor growth curves for 4T1 tumors in mice after various treatments indicated. (G)
Survival rate of different groups of 4T1 bearing mice. Data represent the mean ± SD. (B−F, n = 6; ***P < 0.001; G, n = 10; ***P < 0.001).
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5G) up to 50 days, showing that 50% the mice in the vacosome
group were still alive. Altogether, these data greatly support
that vacosome-immunized mice can more effectively fight
against cancer challenge in the aggressive 4T1 tumor model
compared to TLR agonist (MPLA@Lip) and antigen (CM).
In order to understand the immunological mechanism
preventing cancer growth in immunized mice, the mice were
sacrificed to collect the spleen and tumor at day 14 post the
4T1 cells injection. Considering the immune response caused
by T cells in tumor treatment, the cytotoxic T cells (CTL,
CD8+ T cells) and the regulatory T cells (Treg) were evaluated
in the tumor by using flow cytometry (Figure 6A−D). We
found that both CM (26.9 ± 1.0%) and MPLA@Lip (31.3 ±
2.1%) promoted the differentiation of CTL compared to the
saline-treated group (19.3 ± 3.5%). In addition, mice treated
with vacosome (39.4 ± 5.4%) showed the highest percentages
of CTL in the tumor area (Figures 6A,B). CTL plays a critical
role in killing target cancer cells; thus an increased percentage
of CTL in the tumor area indicates stronger immune activation
and antitumor ability.39 Furthermore, Foxp3 was used as a
marker to classify CD4+ T cells into effective T cells
(CD3+CD4+Foxp3−) that can promote the immune response
and Treg (CD3
+CD4+Foxp3+), which mainly shut down the
immune response.40 As shown in Figures 6C,D, saline groups
showed a much higher percentage of Treg (66.2 ± 5.0%) than
CM (57.2 ± 2.4%) and MPLA@Lip (48.7 ± 2.8%) groups.
The amount of Treg decreased to around 38.9 ± 6.7% in the
vacosome groups, which indicates that vacosome-immunized
mice have reduced immune suppression in the tumor area.
Moreover, the ratio between CD8+ T cells and Treg was
calculated in the collected tumor tissues (Figure S3b). The
BALB/c mice treated with the vacosome exhibited the highest
ratio compared to the mice treated with other formulations,
which indicate the more antitumor microenvironment in the
vacosome-preimmunized BALB/c model. Additionally, as the
immunohistochemistry staining of vacosome groups exhibited
(Figure S5), CD3+, CD4+, and CD8+ T cells can be observed
in the tumor tissue, which could be related to the prolonged
survival period and limited tumor growth.
An important role of vaccination is the ability to make the
immune system acquire immune memory, which is critical for
cancer prevention. Thus, it is meaningful to evaluate the
immune memory induced by the various formulations
prepared. According to the functionality, proliferation, and
migration capabilities, memory T cells are classified into
central memory T cells (TCM, CD3
+CD8+CD62L+CD44+) and
effector memory T cells (TEM, CD3
+CD8+CD62L−CD44+).41
As an important immune organ, spleens were collected to
measure the ratios of both TCM and TEM cells (Figures 6E,F).
We found that mice treated with the vacosome showed a
higher TEM percentage (70.4 ± 6.0%) than mice treated with
CM (38.8 ± 4.4%), MPLA@Lip groups (49.5 ± 5.4%), and
saline (27.8 ± 6.0%) groups. TEM are differentiated from the
CD8+ T cells that are stimulated by antigens for long-term
memory. In addition, the large number of TEM are quickly
expanded when they are re-exposed to their cognate antigen.
TEM can appear in both lymphoid and nonlymphoid tissues
and generate immediate protection by secreting cytokines,
such as IFN-γ.42 All these indicate that after 28 days of
vaccination by the vacosome, the immunized BALB/c mice
generated immune memory. Thereby, when these mice were
challenged by the 4T1 cells, TEM were quickly expanded
against 4T1 cells. Overall, these results indicate that the
effective prophylactic effects of the vacosome are attributed to
a well-established immune memory and full-activated immune
response.
Figure 6. Immune response caused by the vacosome in the tumor and spleen area. Representative flow cytometry data of (A) CD8+ T cells in the
tumor areas (B). Statistical data of CD8+ in the tumor areas. (C) Treg in the tumor areas. (D) Statistical data of Treg in the tumor areas. (E) TCM
and TEM in the spleen. (F) Statistical data of TCM and TEM in the spleen. Data represent the mean ± SD (n = 5; ***P < 0.001).
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3. CONCLUSIONS
In this study, we showed that the vacosome is able to
effectively enhance immune response and establish immune
memory against a 4T1 challenge. The administration of the
vacosome can improve the activation of APCs, leading to an
increased priming of CD8+ T cells. Furthermore, immunization
with the vacosome resulted in increased priming of the TEM
and reduction in the intratumoral Treg, which improve the
antitumor efficiency compared to CM or MPLA@Lip alone.
The vacosome platform provides a promising candidate for the
clinical translation of cancer vaccine, for example, the
vacosome system could be developed as a postoperative
cancer vaccine in preventing tumor recurrence. Specifically,
after the surgery, the cancer cell membranes could be isolated
from the patient tumor tissues and then synthesized with
MPLA to develop the personalized vacosome in preventing
tumor recurrence. As a result, the synthesis process is
convenient, and the materials are accessible and safe, for
example, MPLA has been approved by FDA as an adjuvant and
the lipids used in this study are commercially available and
generally recognized as safe.
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Sierra, J.; Briones, J. Dendritic Cells Combined with Tumor Cells and
α-galactosylceramide Induce a Potent, Therapeutic and NK-cell
Dependent Antitumor Immunity in B cell Lymphoma. J. Transl. Med.
2017, 15, 115.
(30) Sallusto, F.; Lenig, D.; Förster, R.; Lipp, M.; Lanzavecchia, A.
Two Subsets of Memory T Lymphocytes with Distinct Homing
Potentials and Effector Functions. Nature 1999, 401, 708−712.
(31) Kuntsche, J.; Horst, J. C.; Bunjes, H. Cryogenic Transmission
Electron Microscopy (cryo-TEM) for Studying the Morphology of
Colloidal Drug Delivery Systems. Int. J. Pharm. 2011, 417, 120−137.
(32) Garris, C. S.; Arlauckas, S. P.; Kohler, R. H.; Trefny, M. P.;
Garren, S.; Piot, C.; Engblom, C.; Pfirschke, C.; Siwicki, M.;
Gungabeesoon, J.; Freeman, G. J.; Warren, S. E.; Ong, S.;
Browning, E.; Twitty, C. G.; Pierce, R. H.; Le, M. H.; Algazi, A. P.;
Daud, A. I.; Pai, S. I.; Zippelius, A.; Weissleder, R.; Pittet, M. J.
Successful Anti-PD-1 Cancer Immunotherapy Requires T cell-
dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12.
Immunity 2018, 49, 1148−1161.
(33) Waldmann, T. A. Cytokines in Cancer Immunotherapy. Cold
Spring Harbor Perspect. Biol. 2018, 10, a028472.
(34) Oh, E.; Oh, J.-E.; Hong, J.; Chung, Y.; Lee, Y.; Park, K. D.;
Kim, S.; Yun, C.-O. Optimized Biodegradable Polymeric Reservoir-
mediated Local and Sustained Co-delivery of Dendritic Cells and
Oncolytic Adenovirus Co-expressing IL-12 and GM-CSF for Cancer
Immunotherapy. J. Control. Release 2017, 259, 115−127.
(35) Miao, L.; Li, J.; Liu, Q.; Feng, R.; Das, M.; Lin, C. M.;
Goodwin, T. J.; Dorosheva, O.; Liu, R.; Huang, L. Transient and
Local Expression of Chemokine and Immune Checkpoint Traps to
Treat Pancreatic Cancer. ACS Nano 2017, 11, 8690−8706.
(36) Pulendran, B.; Ahmed, R. Translating Innate Immunity into
Immunological Memory: Implications for Vaccine Development. Cell
2006, 124, 849−863.
(37) Church, S. E.; Jensen, S. M.; Twitty, C. G.; Bahjat, K.; Hu, H.-
M.; Urba, W. J.; Fox, B. A. Multiple Vaccinations: Friend or Foe.
Cancer J. 2011, 17, 379−396.
(38) Green, D. R.; Ferguson, T.; Zitvogel, L.; Kroemer, G.
Immunogenic and Tolerogenic Cell Death. Nat. Rev. Immunol.
2009, 9, 353−363.
(39) Brown, M. C.; Holl, E. K.; Boczkowski, D.; Dobrikova, E.;
Mosaheb, M.; Chandramohan, V.; Bigner, D. D.; Gromeier, M.; Nair,
S. K. Cancer Immunotherapy with Recombinant Poliovirus Induces
IFN-Dominant Activation of Dendritic Cells and Tumor Antigen-
Specific CTLs. Sci. Transl. Med. 2017, 9, No. eaan4220.
(40) Zhu, J.; Paul, W. E. Heterogeneity and Plasticity of T Helper
Cells. Cell Res. 2010, 20, 4−12.
(41) Klebanoff, C. A.; Gattinoni, L.; Torabi-Parizi, P.; Kerstann, K.;
Cardones, A. R.; Finkelstein, S. E.; Palmer, D. C.; Antony, P. A.;
Hwang, S. T.; Rosenberg, S. A.; Waldmann, T. A.; Restifo, N. P.
Central Memory self/tumor-reactive CD8+ T cells Confer Superior
Antitumor Immunity Compared with Effector Memory T cells. Proc.
Natl. Acad. Sci. U.S.A. 2005, 102, 9571−9576.
(42) Sathaliyawala, T.; Kubota, M.; Yudanin, N.; Turner, D.; Camp,
P.; Thome, J. J. C.; Bickham, K. L.; Lerner, H.; Goldstein, M.; Sykes,
M.; Kato, T.; Farber, D. L. Distribution and Compartmentalization of
Human Circulating and Tissue-resident Memory T cell Subsets.
Immunity 2013, 38, 187−197.
ACS Applied Materials & Interfaces www.acsami.org Research Article
https://dx.doi.org/10.1021/acsami.0c15057
ACS Appl. Mater. Interfaces 2020, 12, 44554−44562
44562
